Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
81.99
-2.76 (-3.26%)
At close: Jan 16, 2026, 4:00 PM EST
83.49
+1.50 (1.83%)
After-hours: Jan 16, 2026, 6:56 PM EST
Protagonist Therapeutics Employees
Protagonist Therapeutics had 126 employees as of December 31, 2024. The number of employees increased by 14 or 12.50% compared to the previous year.
Employees
126
Change (1Y)
14
Growth (1Y)
12.50%
Revenue / Employee
$1,660,452
Profits / Employee
$364,357
Market Cap
5.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 126 | 14 | 12.50% |
| Dec 31, 2023 | 112 | 7 | 6.67% |
| Dec 31, 2022 | 105 | -13 | -11.02% |
| Dec 31, 2021 | 118 | 39 | 49.37% |
| Dec 31, 2020 | 79 | 6 | 8.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PTGX News
- 4 days ago - Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - Accesswire
- 13 days ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire
- 6 weeks ago - Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Business Wire
- 2 months ago - Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 2 months ago - Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Accesswire
- 3 months ago - Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make - Seeking Alpha
- 3 months ago - Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Benzinga